SK
SKYE.US Skye Bioscience, Inc. Common Stock
- Market cap
- USD 4.42M
- P/E
- -
- P/B
- 3.51x
- ROE
- -2,276.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SKYE.US undervalued?
Graham numberThe Graham number of Skye Bioscience, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Skye Bioscience, Inc. Common Stock fundamental analysis
No fundamental analysis for Skye Bioscience, Inc. Common Stock yet.
Skye Bioscience, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues wi…
Full company profileSkye Bioscience, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Skye Bioscience, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -14.9K | -8.04K | -1.54K | -1.46K | -1.87K | -34.1K | -115K | -124K | -299K | -723K | - |
| Operating Income | -4.47M | -3.86M | -4.69M | -6.63M | -6.29M | -7.85M | -18.3M | -34.7M | -30.2M | -58.2M | -38.3M |
| EBITDA | - | -3.08M | -4.69M | 2.04M | -5.85M | -7.72M | -18.7M | -36.6M | -25.3M | -55.2M | -37.2M |
| Net Income | -3.18M | -3.09M | -19.2M | 1.05M | -6.56M | -8.52M | -19.5M | -37.6M | -26.6M | -55.9M | -31.0M |
| EPS | -319 | -205 | -292 | 16 | -57 | -42 | -0.04 | -43 | -5.83 | -11 | -6.20 |
| Balance Sheet | |||||||||||
| Total Assets | 323K | 557K | 1.96M | 2.00M | 2.67M | 9.86M | 9.11M | 11.9M | 72.8M | 28.3M | 5.07M |
| Total Liabilities | 1.77M | 1.36M | 17.5M | 1.45M | 2.22M | 3.99M | 12.1M | 14.1M | 4.61M | 8.29M | 3.71M |
| Shareholders' Equity | -1.45M | -800K | -15.6M | 548K | 451K | 5.86M | -3.01M | -2.13M | 68.2M | 20.0M | 1.36M |
| Cash & Short-term Investments | 64.8K | 260K | 1.85M | 1.83M | 2.47M | 8.98M | 1.24M | 1.26M | 68.4M | 25.7M | 4.82M |
| Total Debt | - | 235K | 1.36M | 387K | 1.50M | 2.14M | 1.93M | 4.62M | 456K | 274K | 9.45K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.55M | -3.30M | -3.94M | -6.03M | -6.05M | -6.47M | -12.7M | -14.0M | -25.2M | -43.1M | -27.7M |
| Capital Expenditure | 11.1K | 19.7K | 4.39K | 7.23K | 7.23K | 90.9K | 28.1K | 12.6K | 1.60M | 6.31K | 8.00 |
| Free Cash Flow | -3.56M | -3.32M | -3.95M | -6.03M | -6.06M | -6.57M | -12.8M | -14.0M | -26.8M | -43.1M | -27.7M |
| Ratios | |||||||||||
| ROE | - | - | - | 192.0% | -1,455.5% | -145.3% | - | - | -39.0% | -279.3% | -2,276.5% |
| ROA | -982.8% | -555.3% | -980.7% | 52.7% | -245.6% | -86.5% | -213.8% | -315.3% | -36.5% | -197.5% | -610.5% |
| Debt to Equity | - | - | - | 0.71x | 3.32x | 0.36x | - | - | 0.01x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Skye Bioscience, Inc. Common Stock dividends
Skye Bioscience, Inc. Common Stock has not paid dividends in the last 9 fiscal years.
Last stock split: 1:8 on Aug 24, 2026.
Who owns Skye Bioscience, Inc. Common Stock
- Insiders 4.99%
- Institutions 44.60%
- Public & others 50.41%
- Shares outstanding 4.42M
- Free float 3.14M
Top funds holding SKYE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RHB Equity Trust | 100K | 2.27% | 0.00% | Jun 2026 |
| Fidelity Extended Market Index | 13.9K | 0.32% | 0.00% | Sep 2026 |
| Abante Quant Value FI | 9.09K | 0.21% | 0.00% | Aug 2026 |
| Fidelity Total Market Index | 3.83K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 3.05K | 0.07% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.86K | 0.06% | -95.92% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 1.45K | 0.03% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 569.00 | 0.01% | 0.00% | Sep 2026 |
| Global FML Fund R | 2.00 | 0.00% | 0.00% | Sep 2026 |
Top institutions holding SKYE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| 5AM Venture Management, LLC | 9.68M | 0.00% | 0.00% | Jun 2026 |
| Versant Venture Management LLC | 2.01M | 45.34% | 0.00% | Jun 2026 |
| Baker Bros Advisors LP | 1.58M | 35.58% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 764K | 17.25% | -0.08% | Jun 2026 |
| Sphera Funds Management Ltd. | 679K | 15.33% | 0.00% | Jun 2026 |
| BlackRock Inc | 233K | 5.26% | -18.61% | Jun 2026 |
| Geode Capital Management, LLC | 218K | 4.92% | -21.35% | Jun 2026 |
| Millennium Management LLC | 199K | 4.48% | -23.11% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 104K | 2.35% | 0.00% | Jun 2026 |
| State Street Corp | 73.8K | 1.67% | -1.99% | Jun 2026 |
| UBS Group AG | 73.8K | 1.67% | +61.27% | Jun 2026 |
| Northern Trust Corp | 56.3K | 1.27% | +179.65% | Jun 2026 |
| Qube Research & Technologies | 43.1K | 0.97% | 0.00% | Jun 2026 |
| SIMPLEX TRADING, LLC | 27.0K | 0.61% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 21.0K | 0.47% | -48.70% | Jun 2026 |
| Engineers Gate Manager LP | 20.2K | 0.46% | 0.00% | Jun 2026 |
| Group One Trading, LLC | 4.59K | 0.10% | -36.31% | Jun 2026 |
| Vanguard Global Advisers, LLC | 4.56K | 0.10% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 3.07K | 0.07% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.47K | 0.06% | -3.14% | Jun 2026 |
Skye Bioscience, Inc. Common Stock company profile
- Company name
- Skye Bioscience, Inc. Common Stock
- Ticker
- SKYE.US
- Exchange
- USA Stocks
- Listed since
- Apr 2, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 11250 El Camino Real, San Diego, CA, United States, 92130
- Phone
- 858 410 0266
- Website
- skyebioscience.com
About Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Skye Bioscience, Inc. Common Stock management
1- Mr. Punit S. Dhillon B.A.President, CEO, Principal Financial & Accounting Officer & Director · born 1980